At the 11th Congress of the European Academy of Neurology, which was held in Helsinki June 21 to June 24, researchers presented new data on using CAR T cells in autoimmune neurological conditions. Read More
At the recent meeting of the Society of Nuclear Medicine and Molecular Imaging, Chinese Academy of Medical Sciences and Peking Union Medical College scientists co-presented a carbonic anhydrase IX (CAIX)-targeting 68Ga/177Lu theranostic pair for clear cell renal cell carcinoma (ccRCC) and its preclinical evaluation. Read More
Cue Biopharma Inc. has received pre-IND feedback from the FDA to discuss the proposed development plan for CUE-401, its lead autoimmune asset. Based on FDA feedback, the company intends to file an IND pending completion of final IND-enabling studies. Read More
Supercede Therapeutics Inc. has released preclinical efficacy data on its small-molecule inhibitor of the Activin receptor type II (ACTRII) to treat obesity. Read More
Bispecific antibodies mimicking coagulation factor VIIIa (FVIIIa) have yielded successful results in the treatment of hemophilia A, but there remain some issues in regard to their production. Read More
Cure Rare Disease has successfully completed a pre-IND meeting with the FDA regarding its investigational gene therapy program for limb-girdle muscular dystrophy type 2I/R9 (LGMDR9). Read More
Glioblastoma is the most frequent and aggressive primary brain cancer in adults, and patients can expect to live shorter than 2 years, regardless of therapy. The cancer can be treated with CAR T cells, but many patients develop resistance because tumors mutate or delete the antigens recognized by the T cells, while the tumor microenvironment suppresses T-cell activity. Read More
MYB is an oncogenic transcription factor that is often aberrantly expressed in hematologic malignancies, mostly in acute myeloid leukemia (AML). Rgenta Therapeutics Inc. recently presented data for RGT-61159, a potent and selective MYB inhibitor compound that demonstrated cell killing across a panel of MYB-overexpressing leukemic cell lines. Read More
Diffuse midline gliomas (DMGs) are pediatric brain tumors with a very dismal prognosis since less than 5% of patients survive 2 years after diagnosis. Radiotherapy remains the standard treatment for DMG, and several combination chemotherapies and single-agent target therapies are currently being explored. Read More
Work at Rubedo Life Sciences Inc. has led to the development of Bcl-2-like protein 1 (Bcl-xl; Bcl-X; BCL2L1) inhibitors acting as senolytic agents and reported to be useful for the treatment of autoimmune disease, cancer, cardiovascular disorders, cognitive disorders, diabetes, inflammatory, metabolic and neurological disorders, among others. Read More
Viva Star Biosciences (Suzhou) Co Ltd. and Viva Star Biosciences (US) Inc. have patented new NLRP3 inflammasome inhibitors reported to be useful for the treatment of neurodegeneration, metabolic diseases, inflammatory disorders, cancer and genetic disorders. Read More
An Anavo Therapeutics BV patent describes new thiophene and thiazole derivatives acting as protein phosphatase 1D (PP-2Cdelta; WIP1) inhibitors. Read More
Haisco Pharmaceutical Group Co. Ltd. has identified new proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase binding ligand coupled to probable global transcription activator SNF2L2 (SMARCA2; BAF190B; SNF2-α)-targeting agent through a linker acting as SMARCA2 degradation inducers and thus reported to be useful for the treatment of lung cancer. Read More
Scientiam Pharma has disclosed new 6-aminophenanthridine derivatives acting as Epstein-Barr nuclear antigen 1 (EBNA-1) inhibitors reported to be useful for the treatment of Epstein-Barr virus (EBV)-associated disorders such as post-transplant lymphoproliferative disorder, multiple sclerosis and infectious mononucleosis. Read More
